A novel receptor for Apo2L/TRAIL contains a truncated death domain - Wikidata - awgldk - TriplyDB

A novel receptor for Apo2L/TRAIL contains a truncated death domain

A novel receptor for Apo2L/TRAIL contains a truncated death domain

http://www.wikidata.org/entity/Q28255451

about

The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease Onto better TRAILs for cancer treatment Targeting the apoptosis pathway in hematologic malignancies Getting TRAIL back on track for cancer therapy Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 Role of nanotechnology and gene delivery systems in TRAIL-based therapies Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells Transcription initiation sites and promoter structure of the human TRAIL-R3 gene Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)Granule exocytosis mediates immune surveillance of senescent cells.Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.The regulation of apoptotic cell death.NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.Role of p53 family members in apoptosis.Safety and antitumor activity of recombinant soluble Apo2 ligand.Maternal plasma soluble TRAIL is decreased in preeclampsia.Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.Apoptosis: implications for inflammatory bowel disease.Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.TRAIL in cancer therapy: present and future challenges.Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

P2860

Q24323040-2167B9F0-2B6D-4D0F-A389-749D66D2AAB0 Q24554360-F481FB79-E6CB-4156-A9F4-F8563E24FF09 Q24798681-BEBFADAF-4B8A-4A7D-A02A-C574194CACA2 Q26747224-600A01CD-6520-4BE8-A60B-957E8E5E9060 Q26768160-F4C37200-50C5-4276-A58B-82C265F100A0 Q27024422-370A12BE-59C2-49BC-A2AF-FEABE3597337 Q27027460-1BBC0C29-9781-4C8E-85E9-382C13218F42 Q27625357-D938F1D8-4E5A-48EA-88BF-BB382CBBBAA3 Q27649718-F78D79AE-26EC-40B2-9B7B-D937BC5BA58F Q28076798-0F82D5C6-FCDF-4B6F-8FDE-AB11EEF2F7DB Q28140698-5837DCCA-7C23-4B4E-88DB-7CA6445E951E Q28179380-96E08C54-EEFD-4E64-98CC-D92C23657B7A Q28189969-6AA2DAF5-6543-43DB-B870-487FEAE63140 Q28192323-2B15A66D-AB42-4A82-BB3D-44BDE66C1AD3 Q28203099-37B32651-96CC-49BA-B023-400066E12470 Q28213507-BCB3C09E-85F0-4F9C-B2F1-243C1B64EDF4 Q28376530-4F7B63F3-2FD2-4DBC-AACC-D107C143935D Q28391040-A954F0C9-51B6-44A2-AEE2-A0E2E845CD97 Q28396942-7DD768BC-B8E2-42A4-B231-A34973D5E9BF Q28505264-3ACD46BE-3ED3-47BC-BFD7-06105CB5DD46 Q30538996-3945DC15-6A9F-49F7-98F2-D913580527A6 Q30586812-8803509E-F5F8-4F8C-9CE4-197198FCB0DE Q31145220-2E9F9A4D-157A-44D1-ABD6-DB2A4C8D5C32 Q33523440-F57F2035-E285-47B0-A457-771E19686708 Q33591623-57350B89-E14C-46BD-9F85-685CFEC98A5D Q33650479-DD56BCFF-FF16-4906-A3E3-13C7275D80F1 Q33721167-99119D33-4919-4A16-8520-DC204B2697F1 Q33729242-89438D85-C6B5-402E-82A2-8563B14AEFBA Q33782305-78517AA2-BD1F-4F78-8F8D-BF459897B25B Q33810088-25D9BAFB-77B9-4675-9F48-15417BFE036C Q33855449-26053076-9C04-4E67-A279-18EAC306ECD3 Q33909572-30626809-ED3F-462F-9978-CCABFB2E397E Q33910907-BD8D8AC3-C793-4A64-8220-D11928B227E9 Q33912038-54B7F963-48A7-45B1-9216-971D1CE16762 Q34015892-6A932A55-8E97-4DE9-AA1B-730EA02F925F Q34132999-F317BDBE-8145-490F-AB4F-3BEF633D3082 Q34266298-12459AF4-992A-439C-A2A1-6A4217B127DE Q34291312-E4D73B5E-8C6D-4F36-A2F0-131937F67367 Q34312459-71FCD0B0-802B-4E8C-94BE-EFBE9714C82B Q34334395-8A6E86D3-C1D1-4A40-9A9D-8B94F97B440F

P2860

A novel receptor for Apo2L/TRAIL contains a truncated death domain

http://www.wikidata.org/entity/Q28255451

description

1997 nî lūn-bûn

@nan

1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@ast

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@en

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@nl

type

label

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@ast

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@en

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@nl

prefLabel

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@ast

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@en

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@nl

P1433

Q28255451-1DD0A37D-0CF9-4C11-92B4-9813D74CB25E

P1476

Q28255451-B555F880-8A24-4786-9700-BF0BF7F33635

P2093

Q28255451-51C336FF-3928-49F1-A451-042BD09B7166

Q28255451-5A68D2CC-2C8E-45B8-8A18-F663DF6FCB5B

Q28255451-5DDE8B03-4473-4793-A1A5-D2E577995ED2

Q28255451-6C3C8180-921E-49CF-A644-08F2C4B58871

Q28255451-6E0CDD02-44CF-4EAB-85A4-F1922F83E7F0

Q28255451-7B135B03-BB4A-4B21-B43C-69A5134E5714

Q28255451-836F9605-9FCE-4B7D-9061-8A8A6FDE9EE2

Q28255451-ABE1DC20-C819-42D4-98F2-E354976B59E7

Q28255451-DE0D6CC0-338A-4499-AC88-D9558A1609CB

Q28255451-E7B06DA3-1031-4DDD-BAFA-5AF09225AC77

P304

Q28255451-46A52330-266A-42A1-947C-00899D58DEC9

P31

Q28255451-58F0B9E5-F5E9-4BFB-A525-0E1CE138C6FF

P3181

Q28255451-FE1D99A2-7B89-4AFD-8DE4-57E90813EB17

P356

Q28255451-D86CA780-A087-4AE2-BB9D-A3A461E96E5D

P407

Q28255451-2C5CD2E6-F2AD-4A44-A81B-5F20B8AB3F20

P433

Q28255451-B2CAD42E-051F-46A4-A687-CABF71E26913

P478

Q28255451-FA85932E-00E1-475A-A660-B59C0956003D

P577

Q28255451-6F5671EC-F236-4CDE-B959-F1C7B5445331

P698

Q28255451-2EB3C853-2657-4013-AD25-244F4DE73F27

P3181

P356

S0960-9822(06)00422-2

P1433

Current Biology

P1476

A novel receptor for Apo2L/TRAIL contains a truncated death domain

@en

P2093

A Ashkenazi

http://www.w3.org/2001/XMLSchema#string

A D Goddard

http://www.w3.org/2001/XMLSchema#string

A Gurney

http://www.w3.org/2001/XMLSchema#string

A Huang

http://www.w3.org/2001/XMLSchema#string

D Baldwin

http://www.w3.org/2001/XMLSchema#string

J P Sheridan

http://www.w3.org/2001/XMLSchema#string

J Yuan

http://www.w3.org/2001/XMLSchema#string

M Skubatch

http://www.w3.org/2001/XMLSchema#string

P Godowski

http://www.w3.org/2001/XMLSchema#string

R M Pitti

http://www.w3.org/2001/XMLSchema#string

P304

1003-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2157027

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0960-9822(06)00422-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

1997-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9382840

http://www.w3.org/2001/XMLSchema#string